Tagged with Pharmaceuticals,

Singapore In an exclusive interview, Zuellig Pharma CEO John Davison provides insight into the new Zuellig Health Solutions unit that is providing strategic, topline-focused services in order to support Pharma companies in the region. He highlights the challenges the industry faces in penetrating the market and how Zuellig Pharma is closing…

Switzerland Outsourcing of API synthesis has stabilized in the decade since Rohner Chem entered the pharma sector in earnest, and according to CEO Daniel Pedrett the company has reached a position where it is faster, more agile and more experienced than the internal supply organizations of many mid-sized innovators. You were…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

Slovakia The basics on the country of Slovakia: name, date of independence, geography, population, currency, language, and capital. Slovakia is well integrated into the international community, with membership of the majority of large transnational institutions. Slovakia is located at the heart of Europe, within a short flight of almost every other…

Switzerland With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market  Manager Giampiero Roncoroni discusses the unique features of the Swiss market, and how a particular focus on the OTC/OTX market has been a key factor of success…

Singapore Takeda’s President of Emerging Markets Business Unit, Giles Platford, speaks about his assignments across various global markets, his leadership philosophy, as well as the impressive international growth of the company.   I feel a strong sense of responsibility and obligation working for a company that has potentially life-saving and life-transforming…

Singapore In an interview with Takeda’s President of Emerging Markets Business Unit, Giles Platford portrays a vitalized focus on emerging markets and explains why those countries are positioned as one of three key growth drivers for the company. With Takeda’s recently unveiled Access-to-Medicines (AtM) strategy, he also characterizes the role of…

Ireland Deirdre Bourke, Country Lead at Eli Lilly’s Irish affiliate, highlights the strategic importance of Ireland to Lilly’s global operations, their exciting upcoming pipeline, the challenges and opportunities she foresees for Lilly in Ireland, and her own professional transition from managing Lilly’s diabetes portfolio to Lilly’s overall commercial activities in Ireland.…

Switzerland With 40 years of history in Switzerland, B Braun serves every hospital in the country and operates three distinct production sites. CEO Madeleine Stöckli discusses her strategy for improving productivity and finding opportunities for growth. Could you please briefly introduce yourself and B Braun Switzerland to our readers? B Braun…

Luxembourg Philippe Sollie reveals the inspirations behind Flen Pharma and how approaching dermatology from a pharmaceutical background has proved beneficial in building an innovative and competitive enterprise.  When you founded Flen Pharma 16 years ago, the company was based in Belgium and was headquartered there until 2012 when you decided to…

Switzerland Sintetica, Switzlerland’s longtime leader in local anesthesia and pain relief with development efforts in neuromodulation, started an ambitious internationalization strategy in 2011. CEO Augusto Mitidieri discusses the company’s expansion progress and highlights areas of unmet medical need around anesthetics. What are the most significant unmet medical needs in the realm…

Ireland Iwer Baecker, MD of Bayer Ireland, outlines the Irish affiliate’s impressive growth in the past few years, the strategy of New Bayer and how it comes into play in Ireland, as well as how Ireland’s small size is not a constraint but rather a huge opportunity to be taken advantage…